18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.
Key claim: 18F-FAPI PET/MRI imaging is being prospectively evaluated as a novel diagnostic tool for assessing systemic fibrosis in myelofibrosis patients, with findings correlated against bone marrow biopsy and clinical prognosis.
Abstract
This study intends to use a prospective, observational, self-controlled, multi-center study design to evaluate the feasibility and diagnostic efficacy of 18F-FDG PET/CT and 18F-FAPI PET/MRI imaging for the evaluation of systemic fibrosis in MF patients based on the results of bone marrow pathological biopsy, and to analyze the relationship between imaging results and clinical prognosis.
Why this matters
Quantitative imaging of fibroblast activation could provide a non-invasive way to assess fibrosis burden in tissues like the spleen and bone marrow, complementing biopsy-based grading. For symptom management, this matters because better characterization of splenic fibrosis may help stratify which patients are likely to benefit from spleen-directed interventions versus those whose symptoms stem from other drivers.